Skip to main content

PMV Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

PMVP$1.22-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets (Unaudited)

Condensed Consolidated Balance Sheets

June 30,2026 (unaudited)December 31,2025
Assets
Current assets:
Cash and cash equivalents$12,469$37,983
Marketable securities, current66,96274,960
Prepaid expenses and other current assets1,9782,284
Total current assets81,409115,227
Property and equipment, net154237
Right-of-use assets209801
Other assets296297
Total assets$82,068$116,562
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$2,020$3,155
Accrued expenses8,3317,857
Operating lease liabilities, current217403
Total current liabilities10,56811,415
Operating lease liabilities, noncurrent—435
Total liabilities10,56811,850
Commitments and contingencies (see Note 6)
Stockholders’ equity:
Preferred stock, $0.00001 par value, 5,000,000 shares authorized at June 30, 2026 and December 31, 2025. No shares issued or outstanding at June 30, 2026 and December 31, 2025.——
Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 53,460,432 and 53,331,766 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively.——
Additional paid-in capital554,160551,082
Accumulated deficit(482,578)(446,454)
Accumulated other comprehensive income (loss)(82)84
Total stockholders’ equity71,500104,712
Total liabilities and stockholders’ equity$82,068$116,562
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.